LGD-4033 vs Turkesterone
The natural-alternative framing, checked from both sides: an unapproved SARM with measured human numbers, against an ecdysteroid whose one human study found nothing.
Short answer
The evidence gap decides this one. LGD-4033 has human clinical data behind it, while turkesterone has only preclinical or minimal evidence, resting mostly on animal or lab work. Someone focused on oral muscle building without steroids has trial data to go on with LGD-4033; turkesterone, marketed for muscle building, is still an early-research option.
LGD-4033
Ligandrol, VK5211, Anabolicum
The best-studied consumer SARM, and the data says what buyers don't expect: +1.21 kg lean mass in 21 days with no strength gain, alongside a 39% HDL drop and dose-dependent testosterone suppression.
Full LGD-4033 evidence reviewTurkesterone
Marketed as a natural anabolic, but the sole human turkesterone study was null; the anabolic buzz is borrowed from a single ecdysterone trial, and 'turkesterone' products are frequently under-dosed or adulterated.
Full Turkesterone evidence reviewLGD-4033 vs Turkesterone: head to head
- FDA status / approved use
LGD-4033
Not approved anywhere; the FDA calls SARM products unapproved drugs; banned in sport at all timesTurkesterone
Sold as a dietary supplement; not an approved drug- Marketed for
LGD-4033
Oral muscle building without steroidsTurkesterone
'Natural' muscle building- Outcome areas
LGD-4033
Muscle / strength / lean mass; Testosterone / male hormones; CardiovascularTurkesterone
Muscle / strength / lean mass- Evidence grade
LGD-4033
Clinical dataTurkesterone
Preclinical / minimal- How it works
LGD-4033
Non-steroidal molecule that binds the androgen receptor, favoring muscle over prostateTurkesterone
Plant steroid proposed to act via estrogen receptor beta; unconfirmed in humans- Route and dosing
LGD-4033
Oral, swallowed rather than injected; once daily in trialsTurkesterone
Oral capsule; label doses of 500–1,000 mg/day are untested- Headline human result
LGD-4033
Lean body mass up 1.21 kg vs placebo at 1.0 mg/day over 21 days in a 2013 trial of 76 men; strength unchangedTurkesterone
No significant effect on IGF-1 or metabolism after single doses in a 2024 study of 11 men- Strongest evidence
LGD-4033
Basaria phase 1 RCT, J Gerontol A 2013LGD-4033 evidence reviewPubMed 22459616Turkesterone
Harris, Muscles 2024 (null). Little or no controlled human outcome data for the marketed useTurkesterone evidence reviewPubMed 40757520- Key safety signal
LGD-4033
Suppresses testosterone and cut HDL 39% in three weeks; case reports of cholestatic liver injuryTurkesterone
Tolerated in short studies; long-term safety and use in women, older adults or medicated people unstudied- How it is obtained
LGD-4033
Sold gray-market as a research chemical; no approved human productTurkesterone
Over the counter as a dietary supplement
| LGD-4033 | Turkesterone | |
|---|---|---|
| FDA status / approved use | Not approved anywhere; the FDA calls SARM products unapproved drugs; banned in sport at all times | Sold as a dietary supplement; not an approved drug |
| Marketed for | Oral muscle building without steroids | 'Natural' muscle building |
| Outcome areas | Muscle / strength / lean mass; Testosterone / male hormones; Cardiovascular | Muscle / strength / lean mass |
| Evidence grade | Clinical data | Preclinical / minimal |
| How it works | Non-steroidal molecule that binds the androgen receptor, favoring muscle over prostate | Plant steroid proposed to act via estrogen receptor beta; unconfirmed in humans |
| Route and dosing | Oral, swallowed rather than injected; once daily in trials | Oral capsule; label doses of 500–1,000 mg/day are untested |
| Headline human result | Lean body mass up 1.21 kg vs placebo at 1.0 mg/day over 21 days in a 2013 trial of 76 men; strength unchanged | No significant effect on IGF-1 or metabolism after single doses in a 2024 study of 11 men |
| Strongest evidence | Basaria phase 1 RCT, J Gerontol A 2013LGD-4033 evidence reviewPubMed 22459616 | Harris, Muscles 2024 (null). Little or no controlled human outcome data for the marketed useTurkesterone evidence reviewPubMed 40757520 |
| Key safety signal | Suppresses testosterone and cut HDL 39% in three weeks; case reports of cholestatic liver injury | Tolerated in short studies; long-term safety and use in women, older adults or medicated people unstudied |
| How it is obtained | Sold gray-market as a research chemical; no approved human product | Over the counter as a dietary supplement |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- Clinical data:
- Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).
- Preclinical / minimal:
- Evidence is largely animal, in-vitro, or anecdotal. Little or no controlled human outcome data for the marketed use.
Our verdict
This is usually presented as a choice and neither side supports one. LGD-4033 is the compound turkesterone is sold as an alternative to, and its 21-day placebo-controlled trial in 76 healthy men put numbers on the trade: 1.21 kg of lean body mass at 1.0 mg daily, no significant strength gain, HDL cholesterol down about 39%, and dose-dependent suppression of testosterone and SHBG — in a compound that is approved nowhere and prohibited in sport at all times. Turkesterone's entire human record is one preliminary study that gave 11 men acute doses and found no significant effect on IGF-1 or resting metabolic rate; the muscle-building reputation is borrowed from a single trial of ecdysterone, a related but different molecule, and independent analyses repeatedly find ecdysteroid products do not contain what the label claims. The value in reading them together is seeing what the word alternative is standing in for: a small measured effect bought with hormonal suppression, set against a claim nobody has properly tested.
LGD-4033 fits if
LGD-4033 is the read for anyone who wants the actual measured trade behind an oral muscle-building compound, including the parts the sales copy omits — no strength gain, and a 39% HDL drop in three weeks.
Turkesterone fits if
Turkesterone is the read for anyone about to buy a natural anabolic and wanting to see how thin the category's evidence really is; on the current data there is no established dose, and the better-evidenced option on that shelf is creatine.
LGD-4033 vs Turkesterone: common questions
- Is either LGD-4033 or turkesterone FDA-approved?
- No. LGD-4033 is not approved anywhere; the FDA calls SARM products unapproved drugs; banned in sport at all times. Turkesterone is sold as a dietary supplement; not an approved drug.
- Which has stronger human evidence, LGD-4033 or turkesterone?
- LGD-4033. It has human clinical data (key source: Basaria phase 1 RCT, J Gerontol A 2013), while turkesterone has only preclinical or minimal evidence (key source: Harris, Muscles 2024 (null)).
- What are the main safety concerns with LGD-4033 and turkesterone?
- LGD-4033 suppresses testosterone and cut HDL 39% in three weeks; case reports of cholestatic liver injury. Turkesterone is tolerated in short studies; long-term safety and use in women, older adults or medicated people unstudied.
Key studies behind each
LGD-4033
- Basaria S, Collins L, Dillon EL, et al. (2013). The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. J Gerontol A Biol Sci Med Sci. PubMed 22459616
- Wen J, Syed B, Leapart J, et al. (2025). Selective Androgen Receptor Modulators (SARMs) Effects on Physical Performance: A Systematic Review of Randomized Control Trials. Clin Endocrinol (Oxf). PubMed 39285652
- Barbara M, Dhingra S, Mindikoglu AL. (2020). Ligandrol (LGD-4033)-Induced Liver Injury. ACG Case Rep J. PubMed 32637435
- Labban H, Kwait B, Paracha A, Islam M, Kim DO. (2024). LGD-4033 and a Case of Drug-Induced Liver Injury: Exploring the Clinical Implications of Off-Label Selective Androgen Receptor Modulator Use in Healthy Adults. Cureus. PubMed 39421081
Turkesterone
- Harris DR, Chapman-Lopez T, Machek SB, et al. (2024). The Effects of Multiple Acute Turkesterone Doses on Indirect Measures of Hypertrophy and Metabolic Measures: A Preliminary Investigation. Muscles. PubMed 40757520
- Isenmann E, Ambrosio G, Joseph JF, et al. (2019). Ecdysteroids as non-conventional anabolic agent: performance enhancement by ecdysterone supplementation in humans. Arch Toxicol. PubMed 31123801
- Parr MK, Zhao P, Haupt O, et al. (2014). Estrogen receptor beta is involved in skeletal muscle hypertrophy induced by the phytoecdysteroid ecdysterone. Mol Nutr Food Res. PubMed 24974955
- Parr MK, Botrè F, Naß A, et al. (2015). Ecdysteroids: A novel class of anabolic agents? Biol Sport. PubMed 26060342
The full evidence reviews
- LGD-4033 (ligandrol): what the human trials actually found
Ligandrol has the best human data of any consumer-available SARM — a 21-day trial and one phase 2. They show a 1.21 kg lean-mass gain, no strength gain, a 39% drop in HDL, and dose-dependent testosterone suppression.
Updated August 2026
- Turkesterone: the 'natural anabolic' that was never really tested
Turkesterone is marketed as steroid-like muscle growth without the side effects — but there are essentially no human turkesterone trials, the buzz is borrowed from a different compound, and many products don't contain what they claim.
Updated August 2026